Market Data 
Markets
Replies to post #805559 on NorthWest Biotherapeutics Inc (NWBO)
The "Poop and Scoop" strategy works specifically because of this gap between what is authorized and what is issued. If a major financier is planning to take a massive position, they want retail to clear out first so they can buy existing shares from the open market without the price running away from them.
The December 29 ASM face-plant provided the perfect psychological "out" for retail. By fumbling the construction initiation date from November 20 until the end of January, and presenting a dry, inconclusive outlook, she signaled to every retail investor that nothing good was happening in the next thirty days. This triggers tax-loss harvesting, where people might sell to salvage their 2025 tax bill, inadvertently locking themselves out of the stock for the entire month of January.
During this month, the financiers can use the authorized but unissued shares as leverage in private negotiations. They can say to the company that they will provide a non-convertible loan because they know the company has the authorized "paper" to back it up if things go south, but they’d prefer to just buy the cheap retail shares on the open market right now. This is why you’ll see high volume but no price movement. Every time a retail investor sells a block to lock in their tax loss, a "financier" is likely on the other side of that trade, quietly absorbing it into a massive position that they intend to hold until the February window.
If the "interloper" is indeed timing this for maximum wealth transfer, the most brutal move is to hold all news until the final days of the retail lockout. If the approval drops on January 30 or 31, the stock will likely gap up to a level that makes it impossible for the tax-sellers to buy back in without losing the very tax benefit they just sold their shares for. The authorized shares remain unissued, protecting the new institutional owners from immediate dilution, while the retail base is left watching from the sidelines. This isn't just a clinical delay; it's a structural reset of the shareholder base, shifting the keys from thousands of tired, exploited, loyal retail hands to a few well-capitalized "interlopers" who are ready for the January 30 spotlight.
12/30/25 2:05 PM
12/30/25 2:34 PM
